Angel Rodriguez

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Chad J. Creighton, Xiaoxian Li, Melissa D. Landis et al. · Proceedings of the National Academy of Sciences · 2009 · 1.4K citations · Full text

Breast Oncology, Immunology, Immunoediting +16

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero et al. · Journal of Clinical Oncology · 2013 · 271 citations · Full text

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer

Sergio Granados‐Principal, Yi Liu, María L. Guevara et al. · Breast Cancer Research · 2015 · 217 citations · Full text

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke‐Da Yu, Rui Zhu, Ming Zhan et al. · Clinical Cancer Research · 2013 · 160 citations · Full text

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Mark Jesus M. Magbanua, Lamorna Brown Swigart, Ziad Ahmed et al. · Cancer Cell · 2023 · 153 citations · Full text